No Data
Qingdao Haier Biomedical Co., Ltd. (688139.SH): No shares were repurchased in December.
Gelonghui, January 2nd丨Qingdao Haier Biomedical Co., Ltd. (688139.SH) announced that in December 2024, the company repurchased shares through the centralized bidding trading method via the Shanghai Exchange. As of December 31, 2024, the company had cumulatively repurchased 1,387,844 shares through the centralized bidding trading method via the Shanghai Exchange, accounting for 0.44% of the company's total share capital of 317,952,508 shares. The highest transaction price was 32.31 yuan/share, the lowest price was 24.64 yuan/share, and the total amount of funds paid was 40,435,4 RMB.
Haier Biomedical Plans to Absorb Subsidiary
Do Its Financials Have Any Role To Play In Driving Qingdao Haier Biomedical Co.,Ltd's (SHSE:688139) Stock Up Recently?
Qingdao Haier Biomedical Co., Ltd. (688139.SH): No shares repurchased in November.
On December 2, Ge Long Hui reported that Qingdao Haier Biomedical Co., Ltd. (688139.SH) announced that in November 2024, the company did not repurchase shares through the Shanghai Stock Exchange trading system in a centralized bidding trading manner. As of November 30, 2024, the company has repurchased a total of 1,387,844 shares of the company through the Shanghai Stock Exchange trading system in a centralized bidding trading manner, accounting for 0.44% of the total share capital of the company of 317,952,508 shares. The highest price for the repurchase transaction was 32.31 yuan per share, the lowest price was 24.64 yuan per share, and the total amount paid was RMB 40,435.
Qingdao Haier Biomedical Co., Ltd. (688139.SH): Core technical staff member Zhang Jiangtao has retired and left the position.
Qingdao Haier Biomedical Co., Ltd. (688139.SH) announced that its core technical staff member Zhang Jiangtao recently... due to personal age reasons.
China Post Securities: The old-for-new policy has entered the implementation phase, and the medical devices sector is expected to enter a period of high performance growth.
It is expected that in December and the first quarter of 2025, various provinces will gradually implement the trade-in policy, relevant hospital tenders will be initiated, and equipment manufacturers are expected to see a large number of trade-in orders in the fourth quarter.
Market Still Lacking Some Conviction On Qingdao Haier Biomedical Co.,Ltd (SHSE:688139)
